Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A More Sensitive Prostate Cancer Test Than PSA: Stockholm 3 (STHLM3)

A More Sensitive Prostate Cancer Test Than PSA: Stockholm 3 (STHLM3)

The prostate-specific antigen (PSA) test is used in prostate cancer screening. However, it has a very high false-positive rate. This can lead to unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers, while high-risk prostate cancers may nevertheless be missed. The aim was therefore to develop a test model that could detect high-risk prostate cancer (Gleason score at least 7) more sensitively than PSA testing alone.

The study published in The Lancet Oncology enrolled men aged 50-69 without prostate cancer; men with prostate cancer were excluded. Within the study, a test model called Stockholm 3 (STHLM3) was developed to improve detection of high-risk prostate cancer. In addition to blood PSA levels, this test takes into account other plasma proteins (hK2, MSMB, MIC1), genetic polymorphisms (232 SNPs) and clinical variables (age, family, past health status, previous prostate biopsy and prostate examination).

The primary objective was to obtain clearer information than the PSA test without reducing sensitivity (the ability to detect disease) in diagnosing high-risk prostate cancer.

Click for Detailed Information About Prostate Cancer Risk Groups.

The research found that the STHLM3 test model gave much more accurate results than PSA testing alone in detecting prostate cancer with a Gleason score of at least 7. In addition, STHLM3 reduced the number of prostate biopsies by %32, decreasing unnecessary biopsies in diagnosing prostate cancer (Gleason score at least 7). This shows that the new test model represents a new step toward individualized, risk-based prostate cancer diagnosis. The study article stated that this new model would begin to be used in Europe during 2016.

Sources

Grönberg H, Adolfsson J, Aly M.
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Lancet Oncol. 2015 Nov 9. pii: S1470-2045(15)00361-7. doi: 10.1016/S1470-2045(15)00361-7.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A More Sensitive Prostate Cancer Test Than PSA: Stockholm 3 (STHLM3)

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy